<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131012</url>
  </required_header>
  <id_info>
    <org_study_id>IND for Celecoxib</org_study_id>
    <nct_id>NCT02131012</nct_id>
  </id_info>
  <brief_title>Intravitreal Celecoxib for Chronic Uveitis</brief_title>
  <acronym>Celecoxib</acronym>
  <official_title>Intravitreal Celecoxib for Chronic Uveitis: A Phase I Investigational Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraocular delivery of celecoxib will be an effective means to treat inflammation and
      macular edema and prevent structural complications and vision loss in patients with chronic
      inflammation or macular edema who are unable to tolerate corticosteroids due to their side
      effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims I: Test the safety of intraocular injection of 1mg and 4mg celecoxib in
      patients who have chronic inflammation or macular edema who are unable to tolerate
      corticosteroids due to their side effects.

      II: Test the efficacy of intraocular 1mg and 4mg celecoxib in treating inflammation or
      structural complications of inflammation (macular edema) in patients who are unable to
      tolerate corticosteroids due to their side effects.

      After investigational new drug application and Vanderbilt Institutional Review Board
      approval, celecoxib will be compounded by the Investigational Drug Service of the Vanderbilt
      Medical Center and packaged in individual sterile single use syringes for intraocular
      injection within 2 hours of preparation. Pharmaceutical grade celecoxib will be obtained from
      the drug manufacturer (Pfizer) with certificate analysis and compounded in sterile dimethyl
      sulfoxide following strict sterile technique.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty recruiting
  </why_stopped>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">November 1, 2016</completion_date>
  <primary_completion_date type="Actual">November 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant will receive an intravitreal injection of the Celecoxib and be followed for any possible adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant will receive the intravitreal injection of celecoxib day 1 and be followed for efficacy. The efficacy will be determined from the ophthalmic exams and aqueous samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-4 mg intravitreal injection ofCelecoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Celecoxib</intervention_name>
    <description>1-4 mg intravitreal celecoxib</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>NSAIDS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic inflammation and/or macular edema despite maximal medical treatment Unable to
             tolerate corticosteroids due to side effects Aphakic or Pseudophakic subjects

        Exclusion Criteria:

          -  15 years or younger Have active ocular infection Pregnancy Phakic subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Stephen J. Kim, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

